March 9 midday announcement overview: Xiangjia Co., Ltd. sold 2.9368 million live poultry units by February 2026

2026-03-11 05:22:21

Abstract generation in progress

Xiangjia Co., Ltd. announced that in February 2026, the company sold 2.9368 million live poultry, with sales revenue of 67.3483 million yuan. The average selling price was 10.5 yuan/kg. Month-over-month changes were -27.17%, -25.46%, and 3.37%, respectively, while year-over-year changes were -23.52%, -5.83%, and 20.43%. The total live poultry sales for February 2026 were 2.9368 million units, with sales revenue of 67.3483 million yuan. In February 2025, live poultry sales were 3.84 million units, with sales revenue of 71.515 million yuan.

Zhongjing Food announced that to thank shareholders for their long-term support and to help them better understand and experience the company’s products, the company has decided to give away Zhongjing American Ginseng for free. As of the market close on March 18, 2026, shareholders registered with 100 or more shares can claim one free package of Zhongjing American Ginseng (10g×10 bags).

Tiany Medical announced that its subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., recently received the “Drug Registration Certificate” issued by the National Medical Products Administration. The drug is Sodium Citrate Hemofiltration Replacement Solution, with main ingredients of sodium chloride and sodium citrate. It is an injectable, 5000ml in volume, classified as a Category 4 chemical drug, with the approval number GuoYaoZhunZi H20263506, valid until March 2, 2031. This product is used in continuous renal replacement therapy (CRRT) to achieve local anticoagulation and replenish replacement fluid. The core component, sodium citrate, binds with calcium ions in the blood to form soluble chelates, reducing free calcium ion concentration in the blood, thereby inhibiting coagulation and achieving local anticoagulation during extracorporeal circulation. This reduces the risk of filter clotting and is especially suitable for blood purification treatments for patients with high bleeding risk.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.